Overview

A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
Phase:
Phase 2
Details
Lead Sponsor:
PTC Therapeutics